Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


You blew it, Pfizer tells AstraZeneca

This article was originally published in Scrip

Executive Summary

Just ahead of the deadline of 5pm 26 May (UK time), Pfizer confirmed the news that everyone had been expecting. Following AstraZeneca's rebuttal of Pfizer's "final" acquisition proposal of 18 May, Pfizer was walking away.

You may also be interested in...

AstraZeneca 2Q: Soriot's In It For The Long Haul

AstraZeneca's CEO used the company's second-quarter earnings call to proclaim his commitment to the business just weeks after rumors spread worldwide that he might take up a vacant chief executive role at a rival firm.

Is BMS The Must Have Immuno-Oncology Accessory Of The Season?

Bristol-Myers Squibb is in the M&A hot seat, and Pfizer could be the one applying fire.

Pharma Earnings Calls Reveal US/EU Trump Divide

Less than a month after his inauguration, President Donald Trump has both unnerved and empowered industry sectors with his immediate actions or divulged potential reforms. Execs offered measured reaction and some speculation during recent earnings calls.

Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts